Clinical trial NCT07014163: Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomas
Official title: Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomas
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Lipoma
Lead sponsor: Espad Pharmed
Sponsor class: INDUSTRY
First posted: 2025-06-10
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: before/after clinical trial
Primary purpose: TREATMENT

Brief summary: Lipoma is a relatively common, slow-growing mesenchymal neoplasm originating from adipose tissue. Patients seek treatment for lipomas for various reasons, such as concerns about their growth and spread, aesthetic issues, or worries about the compressive effects of the lipoma. Lipomas are typically removed surgically through excision, which can have complications including bleeding, infection, scarring, and recurrence. Other mentioned treatment methods include liposuction, laser, and medicinal approaches.

Purified synthetic deoxycholic acid has been introduced as the first pharmacological intervention approved by the FDA for the reduction of submental fat. Deoxycholic acid is a type of bile acid that, due to its ability to cause non-selective cell lysis and disruption of adipocyte membranes (adipocytolysis), leads to emulsification of fat in the intestine.

This is an interventional (pre-post), single-arm, and open-label study to evaluate the efficacy and safety of Embella (Deoxycholic acid, produced by Espad Pharmed Co.) for the management of superficial lipomas.


Eligibility criteria: Inclusion Criteria:

1. Men and women aging between 18 to 65 years
2. Having at least one lipoma (based on clinical and sonographic diagnosis), which is accessible for treatment and assessment and is quantifiable along at least 2 perpendicular diameters and lower than 2 centimeter in depth, with the following characteristics:

   * History of slow growth followed by dormancy
   * Being stable for at least 6 months
   * Greatest length by greatest perpendicular width between 4 and 4 square centimeters
   * Inclusive discrete, oval to rounded in shape, not hard or attached to underlying tissue
   * Located on the trunk, upper and lower limbs, far from main and vulnerable neurovascular structures
3. Stable body weight with a body mass index of less than 30 kg/m² in the past three months
4. Signed informed consent
5. Ability to follow study instructions and likely to complete all required visits
6. Agreement to abstain from any treatment for lipomas during the study

Exclusion Criteria:

1. Any medical and physical conditions (for example, high blood pressure or respiratory, cardiovascular, liver, neurological, or thyroid disorders) that, in the opinion of the attending physician, affect the evaluation of the efficacy and safety of the product.
2. Known allergy or sensitivity to the study medication or its components
3. Females who are pregnant or breastfeeding, or expecting to conceive children within the projected duration of study
4. Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study and for the duration of the study.
5. Previous treatment for lipomas
6. Subjects planning a surgical procedure for lipoma during the study or at any time that may affect the evaluation
7. Subjects with volume deficit due to trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome) or HIV-related disease
8. Evidence of recent alcohol or drug abuse
9. Medical and/or psychiatric problems that are severe enough to interfere with the study results
10. Known bleeding disorder or receiving medication that will likely increase the risk of bleeding after injection
11. Having a tendency to develop hypertrophic scarring
12. Having a history of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), hyaluronic acid products, or Streptococcal protein
13. Having an active inflammation, dermatoses, infection, cancerous or precancerous lesion, or unhealed wound in the site of lipoma
14. Having a condition or being in a situation that, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Primary outcomes:
measure: Percentage of calculated volume change of lipoma in participants
timeFrame: Baseline and week 16
measure: Percentage of lipoma size change in participants
timeFrame: Baseline and week 16
measure: Percentage of participant with lipoma size change more than 50%
timeFrame: Baseline and week 16
measure: Score of patient satisfaction
timeFrame: Week 16
Secondary outcomes:
measure: Percentage of participants requiring touch-up injection
timeFrame: Week 4 and week 8
measure: Percentage of participants requiring surgical removal
timeFrame: Week 16
measure: Number of injections needed to achieve favorable result
timeFrame: Week 16
measure: The change in diameter of lipoma compared to baseline
timeFrame: Baseline, week 4, and week 8
measure: The change in volume of lipoma compared to baseline
timeFrame: Baseline, week 4, and week 8
measure: The change in depth of lipoma compared to baseline
timeFrame: Baseline, week 4, and week 8
measure: Safety assessment by evaluation of the severity of adverse events (AEs)
timeFrame: Screening visit, Visit 1 (Day 0), Visit 2 (week 4), Visit 3 (week 8), Visit 4 (week 16)
measure: Safety assessment by evaluation of the seriousness of adverse events (AEs)
timeFrame: Screening visit, Visit 1 (Day 0), Visit 2 (week 4), Visit 3 (week 8), Visit 4 (week 16)
measure: Safety assessment by evaluation of causality of adverse events (AEs)
timeFrame: Screening visit, Visit 1 (Day 0), Visit 2 (week 4), Visit 3 (week 8), Visit 4 (week 16)
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Orchid Pharmed, Medical Department
city: Tehran
country: Iran, Islamic Republic of
facility: Razi hospital
Study officials:
affiliation: Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
name: Kamran Balighi
role: PRINCIPAL_INVESTIGATOR
References: